Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer:a systematic review by  et al.
 
 
University of Birmingham
Statistical analysis of patient-reported outcome data
in randomised controlled trials of locally advanced
and metastatic breast cancer
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life
Endpoints Data Consortium (SISAQOL); Pe, Madeline; Calvert, Melanie
DOI:
10.1016/S1470-2045(18)30418-2
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data
Consortium (SISAQOL), Pe, M & Calvert, M 2018, 'Statistical analysis of patient-reported outcome data in
randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review', The Lancet
Oncology, vol. 19, no. 9, pp. e459-e469. https://doi.org/10.1016/S1470-2045(18)30418-2
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
1 
 
Current State of Statistical Analysis of Patient Reported Outcomes Data in Cancer 
Randomized Controlled Trials on Locally Advanced and Metastatic Breast Cancer – A 
Systematic Review 
Madeline Pe1, Lien Dorme1, Corneel Coens1, Ethan Basch2, Melanie Calvert3, Alicyn Campbell4, 
Charles Cleeland5, Kim Cocks6, Laurence Collette1, Linda Dirven7, Amylou C Dueck8, Nancy 
Devlin9, Hans-Henning Flechtner10, Carolyn Gotay11, Ingolf Griebsch12, Mogens Groenvold13, 
Madeleine King14, Michael Koller15, Daniel C Malone16, Francesca Martinelli1, Sandra A 
Mitchell17, Jammbe Z Musoro1, Kathy Oliver18, Elisabeth Piault-Louis4, Martine Piccart19, 
Francisco L Pimentel20, Chantal Quinten21, Jaap C Reijneveld22,  Jeff Sloan23, Galina Velikova24,  
and Andrew Bottomley1   
for the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of 
Life Endpoints Data (SISAQOL) Consortium. 
1European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium  
2Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA  
3Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, College 
of Medical and Dental Sciences, University of Birmingham, UK 
4Genentech, a member of the Roche group, San Francisco, CA, USA 
5Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 
Houston, TX, USA 
6Adelphi Values, Bollington, Cheshire, UK 
7Leiden University Medical Center/Haaglanden Medical Center, Leiden/The Hague, Netherlands 
2 
 
8Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA 
9Office of Health Economics, London, UK 
10Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Magdeburg, 
Magdeburg, Germany 
11School of Population and Public Health, University of British Columbia, Vancouver, BC, 
Canada 
12Boehringer Ingelheim International GmBH, Ingelheim, Germany 
13Department of Public Health and Bispebjerg Hospital, University of Copenhagen, Copenhagen, 
Denmark 
14School of Psychology and Sydney Medical School, University of Sydney, Sydney, NSW, 
Australia 
15Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany 
16College of Pharmacy, University of Arizona, Tucson, AZ, USA 
17Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer 
Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA 
18International Brain Tumour Alliance, Surrey, UK 
19Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium 
20Blueclinical Phase I, Porto, Portugal; Centro de Estudos e Investigação em Saúde da 
Universidade de Coimbra, Portugal. 
3 
 
21European Centre for Disease Prevention and Control, Surveillance and Response Support Unit, 
Epidemiological Methods Section, Stockholm, Sweden 
22VU University Medical Center, Department of Neurology & Brain Tumor Center, Amsterdam, 
The Netherlands 
23Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA  
24Leeds Institute of Cancer and Pathology, University of Leeds, St James’s Hospital, Leeds, UK. 
 
 
 
Corresponding author: Dr. Madeline Pe 
Quality of Life Department, European Organisation for Research and Treatment of Cancer 
Avenue E. Mounier 83/11, 1200 Brussels, Belgium 
madeline.pe@eortc.org 
Tel: +32 2 774 1544 
 
Keywords 
Health-Related Quality of Life, Advanced Breast Cancer, Systematic Review, Randomized 
Controlled Trials, Statistical Methodology, Patient Reported Outcomes 
 
 
  
4 
 
 
Summary 
Although patient reported outcomes (PROs) such as health-related quality of life (HRQOL) are 
important endpoints in randomized controlled trials (RCTs), there is little consensus about 
analysis, interpretation and reporting of these data.  
A systematic review was conducted to assess variability, quality, and standards of PRO data 
analyses in advanced breast cancer RCTs. We searched through PubMed for English language 
articles published in peer-reviewed journals between January 2001 and October 2017. Eligible 
articles reported PRO results from RCTs involving adult advanced breast cancer patients 
receiving anti-cancer treatments with reported sample sizes of at least 50 patients.  
Sixty-six RCTs met the selection criteria. A small number of RCTs reported a specific PRO 
research hypothesis (8/66, 12%). There was heterogeneity in the statistical methods used to 
assess PRO data, with a mixture of longitudinal and cross-sectional techniques. Not all articles 
addressed the problem of inflated type I error resulting from multiple testing.  Fewer than half of 
RCTs reported the clinical significance of their findings (28/66, 42%).  The majority of trials did 
not report how missing data was handled (48/66, 73%).  
Our review demonstrates a need to improve standards in analysis, interpretation and reporting of 
PRO data in cancer RCTs. Lack of standardization makes it difficult to draw robust conclusions 
and compare findings across trials. The Setting International Standards in the Analyzing Patient-
Reported Outcomes and Quality of Life Data (SISAQOL) Consortium was set up to address this 
need and develop recommendations on the analysis of PRO data in RCTs. 
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Introduction 
In a breakthrough report, the Institute of Medicine highlighted patient-centered care as a critical 
component of quality health care1. Patient-centered care is defined as “respectful of, and 
responsive to the individual patient preferences, needs, and values and that patient values guide 
all clinical decisions” 1. The incorporation of patient reported outcomes (PROs) in randomized 
controlled trials (RCTs) is one concrete way of responding to this imperative. Increasingly, PRO 
endpoints are being included in RCTs to assess clinical benefit alongside overall and 
progression-free survival2. PRO is any outcome that is reported directly by the patient3,4. By 
including PRO endpoints, such as health-related quality of life (HRQOL), the patient’s 
perspective is obtained, providing better patient information and supporting shared decision 
making in the development of new therapies5,6.  
However, the lack of standards and clear guidelines on how these patient-reported data should be 
analyzed and interpreted in RCTs diminishes their recognized and important value by making it 
difficult to compare results across trials and draw conclusions about the patient experience of 
new types of cancer treatment7. Data generated from certain PROs, such as HRQOL, are 
complex: they (a) are multidimensional, with several subscales to characterize patients’ 
symptoms and their impact on aspects of patient functioning; (b) require repeated measurements 
in order to capture changes in these outcomes; and (c) are prone to missing data since it is often 
difficult to obtain complete PRO follow-up data from all randomized patients8,9. Inappropriate 
handling of these critical statistical issues could bias findings and lead to inaccurate conclusions. 
Current guidelines do not provide concrete suggestions on how to deal with statistical issues 
concerning PROs and need to be supplemented with more detailed strategies on how to address 
these concerns3,10. 
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The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life 
Endpoints Data for Cancer Clinical Trials (SISAQOL) Consortium was established to respond to 
a clear need to develop standards, guidelines, and recommendations for the analyses of PRO data 
in cancer RCTs. This Consortium involves a wide range of international experts - leading PRO 
researchers and statisticians as well as key individuals from different international oncological 
and medical societies, advisory and regulatory bodies, academic societies, the pharmaceutical 
industry, cancer institutes, and patient advocacy organizations11.  A key task identified by the 
Consortium was to undertake systematic literature reviews to describe the current state of PRO 
analyses in RCTs of cancer treatment. The current article examines how analyses of PRO such as 
HRQOL are conducted in RCTs, in this case using anti-cancer treatments for advanced breast 
cancer as an example set of trials commonly seen in the literature. Since maintaining HRQOL is 
important in the care of advanced breast cancer patients, it was a reasonable expectation that a 
considerable number of advanced breast cancer RCTs would have included PROs in their 
assessments 12. 
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Methods 
Search strategy and selection criteria 
We followed the methodology noted in the guidelines for the Cochrane Handbook for Systematic 
Reviews of Interventions13 and the results of this review are reported in accordance with 
PRISMA guidelines (see Appendix page 35-36 for the PRISMA checklist) 14. We did not publish 
a review protocol for this study. A literature search was performed in PubMed on March 30, 
2016 (and updated on February 7, 2018) with the following keywords: (quality of life[MeSH 
Terms] OR quality of life[Text Word] OR patient reported outcomes[Text Word]) AND 
(advanced[All Fields] OR metastatic[All Fields]) AND breast cancer[Text Word] AND 
(Randomized Controlled Trial) AND (breast neoplasm[MeSH Terms]) AND (Clinical 
Trial[ptyp] AND ("2001/01/01"[PDat] : "2017/10/30"[PDat]) AND Humans[Mesh]). Using this 
search strategy, 323 potentially eligible articles were identified. Checking of references of 
publications were also undertaken. In addition, we performed a Web of Science search at a later 
date (April 22, 2018), but no further articles were found. 
The inclusion and exclusion criteria for the RCTs were similar to that of Ghislain and 
colleagues15.  The inclusion criteria were: articles should report PRO findings from RCTs 
involving adult advanced breast cancer patients (18 years or older), receiving anti-cancer 
treatments (chemotherapy, targeted therapy, endocrine therapy) with sample sizes of at least 50 
patients. Advanced breast cancer refers to either metastatic breast cancer or locally advanced 
breast cancer (see ESO-ESMO international consensus guidelines for more information)12. Only 
articles published in a peer-reviewed journal between January 2001 and October 2017 were 
included, regardless of starting or completion date of the study. It was originally considered to do 
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a search from 1997 to have exactly 20 years of review. However, due to the difficulty of 
retrieving articles before 2001, it was decided to begin the search from 2001. 
Exclusion criteria were any RCTs which evaluated psychological, supportive or supplementary 
interventions. Supplementary treatments were defined as any other interventions that did not 
include anti-cancer therapy. Purely methodological or review publications were also excluded. 
Quality-adjusted life years (QALY) endpoints were not considered as PRO endpoints. 
Publications that reported interim analysis or the analyses of subgroups of patients (i.e., 
subgroups within the PRO cohort) were excluded since we wanted to limit the reporting to the 
top-level PRO results of the RCTs. Figure 1 presents the search strategy flowchart and the 
inclusion and exclusion criteria.  
Two reviewers (MP and LDo) received the initial list of the 323 potentially eligible articles and 
the list of inclusion and exclusion criteria. They independently screened the articles based on 
these criteria. One reviewer (LDo) checked both assessments for any disagreements. Any 
disagreements were resolved through discussion. A third reviewer (CC) was available when no 
consensus could be reached. 
 
[Insert Figure 1 here] 
Evaluation criteria were adapted from previous reviews16,17 with adjustments to enable in-depth 
assessment of statistical issues critical for PRO analysis. The initial data extraction sheet was 
developed by MP and CC and pilot-tested on three randomly-selected included studies and was 
further refined. This resulted in 23 evaluation criteria, classified into five broad categories: (1) 
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general description of the article, (2) reporting of research objectives, (3) statistical analysis and 
clinical relevance, (4) baseline assessment, and (5) assessing the amount of, and handling of 
missing data (see Appendix, page 29-34, for more details on the list of variables that were 
extracted). Two reviewers (MP and LDo) independently evaluated all identified studies on this 
predefined checklist of 23 criteria. One reviewer (LDo) checked the completed data extraction 
sheets for any disagreements.  In case of disagreement, the article was reassessed by both 
reviewers together. If no consensus could be reached, a third reviewer (CC) served as a mediator 
to resolve disagreements.  
When multiple publications for one RCT were identified, the article with the more 
comprehensive PRO statistical reporting was included in the review (see articles with bold 
formatting in the Appendix, page 1-28).Therefore, findings reported in this systematic review are 
based on the number of unique RCTs.  
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Results 
Table 1 summarizes the overall main findings of this systematic review. To assess whether 
practices were improving over time, results were grouped into three periods (2001-2006; 2007-
2012; 2013-2017) in Table 2.  Details about individual papers included in this review are in the 
Appendix, page 1-28. 
Descriptive Statistics 
The search identified 335 eligible articles, of which a total of 66 eligible RCTs in advanced 
breast cancer were included, involving a total of 26,905 patients. No disagreements occurred 
between the 2 independent reviewers. The sample size ranged between 66 and 1102, with an 
average of 407.  From the 66 trials, 12 were considered to be practice changing trials. The most 
commonly used PRO measures were two cancer-specific HRQOL questionnaires: the EORTC 
QLQ-C30 (35/66, 53%) and the FACT-B (22/66, 33%). Almost half of the RCTs (27/66, 41%) 
used multiple assessment tools to measure PROs, of which six trials (6/27, 22%) used an 
instrument that was not validated (e.g., ad-hoc trial specific checklists) in addition to a validated 
questionnaire. The majority of the PRO endpoints were reported as secondary endpoints (46/66 
trials; 70%), with only three RCTs using a PRO as a primary endpoint (3/66, 5%). The other 
RCTs either reported PRO as an exploratory endpoint (3/66, 5%) or did not clearly report the 
PRO endpoint (14/66, 21%). 
[Insert Table 1 here] 
Reporting of research objectives  
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Only eight of 66 RCTs (12%) reported a hypothesis specific enough to inform the analysis of the 
PRO endpoint (i.e., the direction of hypothesis is stated with the domain of interest and specified 
time frame). The majority of the articles either reported a broad hypothesis (25/66, 38%; e.g., “to 
evaluate HRQOL between treatment arms”) or no hypothesis (33/66, 50%).  The majority of 
RCTs failed to report a specific PRO hypothesis, and there was no consistent improvement over 
time (2001-2006: 0/20, 0%; 2007-2012: 4/24, 17%; 2013-2017: 4/22, 18%).  
Statistical analysis and clinical relevance 
The majority of the trials (59/66, 89%) reported analyzing multivariate data, with multiple PRO 
scales/domains and/or with repeated assessments, to assess the PRO endpoint. Scales/domains 
refer to PRO variables that were analyzed in the trial. Thirty-eight RCTs analyzed multiple PRO 
scales/domains (38/66, 58%); and 21 RCTs analyzed a single PRO scale/domain (21/66, 32%). 
Among the 38 RCTs that used multiple PRO scales/domains, only six employed a statistical 
correction to correct for multiple testing (6/38, 16%). Two RCTs reported PROs as an 
exploratory endpoint and assessed multiple outcomes. It can be argued that exploratory 
endpoints do not have to correct for multiple testing. Results remained relatively the same after 
removing these two exploratory endpoints from the total score of PROs that assessed multiple 
outcomes (6/36, 17%). Combined, these numbers demonstrate that 27 of the 66 trials (41%) 
addressed the issue of multiple testing either by statistically correcting for multiple 
scales/domains or assessing only one scale/domain (often identified a priori as the most relevant 
scale/domain). There was no clear pattern in these findings (2001-2006: 11/20, 55%; 2007-2012: 
7/24, 29%; 2013-2017: 9/22, 41%).  
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Fifty-three RCTs analyzed data with repeated assessments at follow-up (>1 follow-up 
assessment; 53/66, 80%); and 8 RCTs analyzed data with a single follow-up assessment (8/66, 
12%). Among the RCTs that used multiple follow-up assessment points in their primary PRO 
analysis, 33 RCTs (33/53, 62%) used a statistical technique that took into account the repeated 
measurements of the data (e.g., time to event, linear mixed models) or statistically corrected for 
them if these repeated measures were tested independently from one another. Combined, these 
findings show that 41 of the 66 trials (41/66, 62%) addressed the issue of multiple testing either 
by statistically correcting for multiple domains, using a statistical technique that took into 
account the repeated measurements, or by analyzing only one follow-up time point. These 
findings remain consistent over time (2001-2006: 13/20, 65%; 2007-2012: 14/24, 58%; 2013-
2017: 14/22, 64%). 
The majority of the RCTs reported PRO scores descriptively (55/66, 83%), such as mean scores 
or mean change scores by trial arms, either on their own or as a support for a comparative 
analysis; and this has been quite consistent over the years (2001-2006: 16/20, 80%; 2007-2012: 
19/24, 79%; 2013-2017: 20/22, 91%). 
When analyzing PRO data, we identified more than six primary statistical analysis techniques. 
The top two most commonly used statistical techniques were (generalized) linear mixed models 
(18/66, 25%) and Wilcoxon ranks sums test/t-test (11/66, 17%). Many RCTs did not report the 
statistical technique used; a p-value was reported but it was not mentioned how this value was 
obtained (15/66, 23%). When comparing findings over time, the most commonly used statistical 
techniques between 2001-2006 were (generalized) linear mixed models (8/20, 40%) and 
Wilcoxon ranks sums test/t-test (5/20, 25%); between 2007-2012 were ANOVA/linear 
14 
 
regression (7/24, 29%), (generalized) linear mixed models (3/24, 13%) and Wilcoxon ranks sums 
test/t-test (3/24, 13%); and between 2013-2017 were (generalized) linear mixed models (7/22, 
32%) and time to event (5/22, 23%). No single technique was used in a majority of the trials. 
Moreover, across all periods, a substantial proportion of RCTs failed to report the statistical 
technique used (2001-2006: 5/20, 25%; 2007-2012: 6/24, 25%; 2013-2017: 4/22, 18%). 
Less than half of the RCTs addressed the clinical relevance of the findings (28/66, 42%). Among 
the trials that reported whether a finding was clinically relevant, the methods used varied: they 
were reported either as a change of X points from baseline (18/28, 64%), an X points difference 
between treatment arms (9/28, 32%) or both (1/28, 4%). The percentage of RCTs reporting the 
clinical relevance of their findings increased somewhat over the years (2001-2006: 5/20, 25%; 
2007-2012: 11/24, 46%; 2013-2017: 12/22, 55%) 
Baseline assessment 
The majority of the RCTs included a baseline PRO assessment (60/66, 91%). From these 60 
studies, 36 (36/60, 60%) compared PRO baseline scores between treatment arms and 13 (13/60, 
22%) included the baseline score as a covariate. That the majority of the RCTs included a 
baseline PRO assessment has been consistent over the years (2001-2006: 18/20, 90%; 2007-
2012: 22/24, 92%; 2013-2017: 20/22, 91%); however, the number of studies reporting whether 
PRO baseline scores are comparable between treatment arms seem to have declined over the 
years (2001-2006: 13/18, 72%; 2007-2012: 14/22, 64%; 2013-2017: 9/20, 45%); and including 
baseline scores as a covariate has not necessarily improved over the years  (2001-2006: 2/18, 
11%; 2007-2012: 6/22, 27%; 2013-2017: 5/20, 25%). 
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Amount of and handling of missing data 
Many studies (24/66, 36%) did not report or did not clearly specify the analysis population for 
the primary PRO analysis; and this is still the case in the recent years (2001-2006: 6/20, 15%; 
2007-2012: 8/24, 33%; 2013-2017: 10/22, 45%). Fourteen RCTs (14/66, 21%) reported using the 
intent-to-treat (ITT) population in their analysis; and a greater number of RCTs reported using a 
modified intent-to-treat (mITT) population (28/66, 42%). These numbers were relatively 
comparable over the years (see Table 2). Five different definitions of mITT were found, 
demonstrating that there is no consistent definition of mITT (64% with baseline PRO and ≥ 1 
post-assessment (18/28); 14% with baseline PRO (4/28); 7% with at least one PRO data point 
(2/28); and 7% with baseline PRO and trial-specific follow-up point of interest (2/28). See 
Appendix, page 21-28, for the analysis population used by each RCT).  
Regarding compliance rates, among the RCTs that assessed baseline PRO (60/66, 91%), twenty-
eight of them (28/60, 47%) reported baseline PRO compliance rates for each treatment arm. 
Nineteen RCTs (19/66, 29%) reported whether compliance rates between treatment groups 
differed throughout the follow-up assessments. Most studies (48/66, 73%) did not report how 
missing data were dealt with. These findings were relatively comparable across the years (see 
Table 2). 
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Discussion 
The aim of this systematic review was to assess the current state of PRO analysis in RCTs in 
advanced breast cancer. Our findings showed that in the 66 eligible RCTs, there was clear 
heterogeneity on how PRO data were analyzed.  
Most trials failed to report a specific research hypothesis (88%), even in the last six years (2012-
2017: 82%). This is consistent with previous reviews18–21. This may reflect lack of knowledge 
about the likely HRQOL trajectory for novel treatments or a lack of consideration of PRO 
specific hypotheses at the design stage and specification in the trial protocol. This is consistent 
with recent reviews of trial protocol content 22,23. Our findings highlight an area of poor practice 
which does not meet ISOQOL and CONSORT-PRO reporting standards 24,25. Failure to state a 
clear PRO hypothesis a priori opens up the possibility that inappropriate statistical techniques 
may be used. For instance, if a study had the objective about HRQOL changes over a six-week 
period, a cross-sectional HRQOL analysis at six weeks is not equivalent to an area under the 
curve analysis within the same time frame; in fact, it is possible that these two analytical 
techniques may yield different results. If the PRO objective is not stated or too vaguely stated, 
different statistical approaches may be reported as equivalent ways of addressing the same PRO 
objective, when in fact, they focus on different aspects of the data; and therefore respond to 
different research objectives. Divergent findings, however, may not necessarily invalidate the 
PRO data analysis but rather illustrate the importance of a well-defined a priori hypothesis, and 
responding to them with an appropriate statistical technique. Therefore, it is critical that 
researchers clearly define their hypotheses and appropriate corresponding statistical analyses in 
the protocol or statistical analysis plan in sufficient detail 26; and results are described in a way 
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that accurately represents the key patterns in the data and able to be understood by non-statistical 
readers.  
The most commonly used statistical technique (linear mixed models) was only employed in 27% 
of the RCTs (18/66). Wilcoxon-ranks-test/t-tests, statistical techniques appropriate for single 
time points or change scores, were also commonly used (11/66, 17%) although this strategy may 
not be appropriate since the majority of the trials involved analyzing data with more than two 
repeated assessments (53/66, 80%). There seems to be an increased interest in the use of time to 
event analysis in the recent years (from 2001-2007: 1/20, 5% to 2013-2017: 5/22, 23%) (see 
Table 2). However, a major concern remains that a number of RCTs (15/66, 23%) did not even 
(clearly) report the statistical technique they used to analyze PRO data, which is still evident in 
the recent years (2013-2017: 4/22, 18%).   
Analysis of a PRO endpoint, such as HRQOL, often involves multiple outcomes. When drawing 
conclusions about treatment efficacy, it is advisable to avoid the risk of accumulating type 1 
errors (false positive findings) by adjusting critical p-values for multiple comparisons when 
multiple outcomes are used to test a multi-dimensional endpoint, such as HRQOL. A large 
number of RCTs did not do this (30/38, 79%); and this has still been the case in the last six years 
(10/11, 91%), which may have led to erroneous conclusions about the PRO endpoint due to 
excess type 1 errors27. Given that results of these RCTs can lead to setting new standards of care, 
this practice should be avoided. On-going work from SPIRIT-PRO to standardize what needs to 
be included in the design stage of a trial (protocol) and statistical analysis plans may help 
promote better reporting on these issues 26.  
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The sample size estimation required for a trial is typically calculated only for the primary clinical 
endpoint. Since PRO endpoints, such as HRQOL, are often secondary endpoints, the sample size 
may be much larger (or smaller) than what is needed for that endpoint. Since statistical 
significance is highly dependent on sample size, having a large sample size can produce 
statistically significant results, but the clinical relevance of the change in the PRO endpoint may 
be negligible28. It is therefore recommended that clinical relevance should always be reported 
alongside statistical significance. Similar to other reviews 18–21,29, our review showed it is still not 
common practice to report the clinical relevance of PRO findings: less than half of the RCTs 
(28/66, 42%) reported whether their findings were clinically relevant; although this practice has 
shown some improvement in the last six years (from 2001-2006: 5/20, 25% to 2013-2017: 12/22, 
55%).  
The majority of the RCTs in this review reported having a baseline assessment (90%) and this 
has been consistent over the years. These findings demonstrate wide acceptance of this practice. 
Assessing baseline (or pre-treatment) scores is essential in any PRO analysis. Since individuals 
can differ in their baseline levels, it is important to take this into account when assessing 
individual changes over time and differences between treatment arms. This makes the statistical 
analysis more efficient by reducing the influence of baseline differences in the analysis30. A large 
number of articles collected baseline PRO information (60/66, 91%) and 40% of RCTs did not 
subsequently check whether there were baseline differences between treatment arms (24/60). 
Additionally, only a small number of trials reported using the baseline PRO scores as a covariate 
(13/60, 22%). These findings remain comparable over the years. This highlights the lack of 
consistency between investigators on how to use baseline information in their analyses.  
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To assess the amount of missing data, it is critical that trials report the set or subset of trial 
participants that will be used in the analysis (the “analysis population”) 31, as well as PRO 
completion (or “compliance rates”) over time32.  Only a small number of the publications used 
intent-to-treat (ITT) as the analysis population (14/66, 21%); and this has still been the case in 
the recent years (2013-2017: 4/22, 18%). Additionally, some papers that purported to use ITT 
apparently did not adhere to the ITT principle (i.e., all randomized subjects should be analyzed 
according to the allocated treatment33). For example, some RCTs reported that they would use 
ITT for analysis, but their statistical techniques removed a patient if an assessment was missing 
(e.g., when a statistical test involves calculating a change score34,35). Probably because of the 
difficulty of using the ITT population for PRO analysis, a number of articles opted for a 
modified intent-to-treat approach (mITT). However, there is no consensus on which mITT 
approach should be used as demonstrated by the variety of ways these RCTs have defined their 
mITT (e.g., patients with baseline PRO; patients with baseline PRO + 1 follow-up assessment). 
 
Compliance rates are another way of understanding the amount of missing data in a trial32. 
However, our findings showed that although more than half of the RCTs reported baseline 
compliance rates, a smaller number of publications reported follow-up compliance rates within 
their time frame of interest; and not all articles compared compliance rates between treatment 
groups. This lack of information on compliance rates makes it difficult to evaluate whether a 
statistical technique is appropriate for the analysis population (e.g., some statistical techniques 
assume that the dataset has no missing data or that missing data is missing completely at random) 
and whether the conclusions are generalizable to the population of interest.  
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Strategies to deal with missing data in the statistical analyses were reported in only 27% of RCTs 
(18/66); and this practice has not changed in the recent years (from 2001-2006: 4/20, 20% to 
2013-2017: 5/22, 23%).  However, it is known that missing data is a challenge in the analysis of 
PRO data in cancer trials8,30,36. As cancer patients often experience disease- and treatment-related 
illness and mortality, missing assessments are often inevitable37. Since missing data can bias 
results, it is strongly advised that sensitivity analyses should be conducted to explore the 
robustness of the primary findings 38. That is, investigators are encouraged to reanalyze the data 
with a statistical model that makes different missing data assumptions than that of the primary 
analysis. If results are reasonably consistent across the different analyses, there is increased 
confidence that the presence of missing data did not compromise the original findings.39 The lack 
of information on how missing data were handled suggests that this problem is often ignored or 
regarded as unimportant when reporting PRO findings. This situation should not be acceptable.  
 
While our review was robust and followed a systematic approach, our work also has several 
limitations. Findings from this review were based on published articles, and the articles selected 
may reflect publication bias, i.e., statistically significant “positive” results tend to have a better 
chance of being published40. Protocols or a priori statistical analysis plans were not checked 
alongside these published reports. It is possible that information classified as “not reported” in 
this review may have been recorded in the protocol, but was not included in the article due to 
space limitations in the journals. However our findings are consistent with systematic reviews of 
protocols 22,23 and other reviews of papers reporting RCTs 18–21,29 demonstrating that these issues 
are indeed prevalent in the PRO field . We excluded non-English publications in our search, so 
some relevant trials may have been excluded. The focus of this systematic review was on 
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advanced breast cancer and thus may not be generalizable to all cancer types, although we have 
no reason to think that the analysis problems reported here would be different in other disease 
sites. Indeed, the converging results from other systematic reviews in different cancer sites point 
toward a general problem that is not specific to one cancer site16,17,19. As there are no agreed-
upon standards on how to conduct analyses of PROs in RCTs, the evaluation criteria of these 
trials were based on authors’ selection of statistical issues that were deemed as critical for the 
analysis of PRO data, but remains broadly in line with on-going work on guidelines for statistical 
analysis plans 26. Although this review focuses on standards in statistical analysis, we would like 
to stress the importance of a high quality study design; and choosing appropriate PRO measures 
and assessment points that capture the impact of both the disease and treatment on the patient 
experience. Even if the most robust statistical approach is used, findings from a RCT would be of 
little relevance if the study design is of poor quality; and inappropriate outcomes and follow-up 
assessment points are used26. 
 
In conclusion, our review highlights the many statistical issues that need to be addressed to 
improve the analysis and interpretation of PRO data, including HRQOL. The lack of consensus 
on how to analyze PRO data makes it difficult to draw robust conclusions regarding PRO 
endpoints and compare findings across trials. Although the increased inclusion of PRO endpoints 
in RCTs is a substantial step toward a more patient-centered approach, standards and guidelines 
are needed for how to analyze PRO data in cancer RCTs. The SISAQOL Consortium was set up 
to address this need and develop recommendations on how to analyze PRO data in RCTs11 and 
will produce such guidelines in the future. 
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